基于Meta分析的复方龙血竭胶囊治疗冠状动脉粥样硬化性心脏病稳定型心绞痛(心血瘀阻证)的药物经济学评价OA

Objective An economic assessment of Compound Longxuejie Capsule was conducted to determine its pharmacoeconomic value in the treatment of stable angina pectoris with coronary atherosclerotic heart disease(heart cardiac blood stasis syndrome).Methods Based on the meta-analysis of compound Longxueji capsule in the treatment of stable angina pectoris with coronary atherosclerotic heart disease(syndrome of blood stasis),the efficacy indicators were obtained.The cost-effectiveness ratio of compound Longxueji capsule and compound Danshen capsule in the treatment of stable angina pectoris with coronary atherosclerotic heart disease(heart cardiac blood stasis syndrome)was calculated,and the decision Tree model was constructed by Tree Age Pro for cost-effectiveness analysis and sensitivity analysis.Results The efficacy of angina pectoris was taken as the short-term efficacy parameter,and the simulation period was 4 weeks(28 d).The results showed that compound Longxuei capsule was better than compound Danshen capsule in improving the efficacy of angina pectoris,and the difference was statistically significant(P＜0.05).The treatment cost of compound Dragon's blood exhaust capsule was higher than that of compound Danshen capsule,and the incremental cost-effectiveness ratio of compound Dragon's blood exhaust capsule to compound Danshen capsule was 3046.91 yuan,which was less than 10%of per capita disposable income.The results of sensitivity analysis show that the results of basic analysis are relatively robust.Conclusion Based on the assumption of per capita disposable income as the patient willing to pay(WTP)threshold in 2020,compound Longxuei capsule may have a cost-effectiveness advantage in the treatment of stable angina pectoris with coronary atherosclerotic heart disease(blood blood stagnation syndrome)compared with compound salvia miltiorrhia capsule.